Roger Adsett Sells 88,060 Shares of Insmed (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM) COO Roger Adsett sold 88,060 shares of Insmed stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total value of $14,497,317.80. Following the sale, the chief operating officer directly owned 106,810 shares in the company, valued at $17,584,130.30. The trade was a 45.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Roger Adsett also recently made the following trade(s):

• On Tuesday, February 3rd, Roger Adsett sold 791 shares of Insmed stock. The shares were sold at an average price of $156.17, for a total value of $123,530.47.
• On Thursday, January 8th, Roger Adsett sold 2,059 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total value of $358,616.03.
• On Wednesday, January 7th, Roger Adsett sold 802 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total transaction of $140,406.14.
• On Tuesday, January 6th, Roger Adsett sold 1,429 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total transaction of $247,688.57.

Insmed Stock Performance

Shares of INSM stock opened at $162.43 on Friday. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $212.75. The stock has a market cap of $35.06 billion, a price-to-earnings ratio of -25.34 and a beta of 1.10. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The firm has a fifty day moving average of $150.30 and a 200-day moving average of $166.67.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The business had revenue of $263.84 million for the quarter, compared to analyst estimates of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. Insmed’s revenue was up 152.6% on a year-over-year basis. During the same quarter last year, the firm posted ($1.32) earnings per share. On average, equities research analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on INSM shares. Cantor Fitzgerald lifted their price objective on Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Wells Fargo & Company cut their target price on Insmed from $208.00 to $175.00 and set an “overweight” rating for the company in a research report on Monday, March 23rd. TD Cowen set a $241.00 price target on Insmed in a research note on Thursday, December 18th. Morgan Stanley upgraded Insmed from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $166.00 to $212.00 in a research report on Monday, March 30th. Finally, UBS Group dropped their price objective on Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a research note on Tuesday, January 6th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $212.67.

Institutional Trading of Insmed

Several hedge funds have recently modified their holdings of the company. CIBC Private Wealth Group LLC boosted its holdings in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 53 shares in the last quarter. CoreCap Advisors LLC acquired a new stake in Insmed during the 4th quarter valued at $27,000. Stone House Investment Management LLC acquired a new stake in Insmed during the 3rd quarter valued at $29,000. SBI Securities Co. Ltd. raised its position in Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 166 shares during the last quarter. Finally, GraniteShares Advisors LLC bought a new position in Insmed in the 4th quarter valued at $30,000.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.